AInvest Newsletter
Daily stocks & crypto headlines, free to your inbox
Curis (CRIS) reported fiscal 2025 Q3 earnings on November 7, 2025, . .
Revenue

Total revenue rose 8.4% to $3.18 million in Q3 2025, . , driven by its core drug development programs.
Earnings/Net Income
, . The company also reduced its net loss to $7.73 million, . This marked a significant step toward financial stability, though losses remain a key concern.
Price Action
, reflecting investor optimism about improved financial performance and clinical progress. However, , .
Post-Earnings Price Action Review
. Over the past three years, , . Backtesting across Q3, Q2, , even amid market volatility. , reinforcing the strategy’s reliability for investors seeking to leverage Curis’s performance.
CEO Commentary
, CLL, and AML clinical trials, . , .
Guidance
. . , 2025, .
Additional News
M&A Activity, managed by O...
IPO Launch:
Lifesciences, a separate entity, , 2025, .Clinical Updates, , 2025.
Get noticed about the list of notable companies` earning reports after markets close today and before markets open tomorrow.

Dec.05 2025

Dec.05 2025

Dec.05 2025

Dec.05 2025

Dec.05 2025
Daily stocks & crypto headlines, free to your inbox
Comments
No comments yet